Physician profile
James C Gekas
NPI 1235248063
$16,953.71
in general payments reported to CMS, 2019-2025
39 companies · $1,616 in 2025
The $1,616 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,822 · 2020: $2,535 · 2021: $3,701 · 2022: $2,464 · 2023: $1,496 · 2024: $1,320 · 2025: $1,616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,307 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,307.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,837.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $2,754.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,410.65 | 2019-2024 | Xifaxan, Trulance |
| Amgen INC. | $1,133.97 | 2019-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $947.05 | 2019-2023 | Arexvy, Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $851.58 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $814.94 | 2019-2024 | Xarelto |
| Abbvie INC. | $576.46 | 2020-2024 | |
| Lilly USA, LLC | $572.65 | 2019-2024 | Jardiance |
| Allergan, INC. | $562.79 | 2019-2020 | |
| Pfizer INC. | $470.47 | 2019-2025 | |
| Esperion Therapeutics, INC. | $463.39 | 2020-2024 | Nexletol |
| Sumitomo Pharma America, INC. | $291.61 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $273.69 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $252.08 | 2024 | Voquezna |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gekas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.